Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
Pentagon rapid-response Ebola medical team was scheduled to begin training at Fort Sam Houston in San Antonio, Texas
Extensively drug-resistant TB (XDR-TB), which is even more expensive and difficult to treat than multi drug-resistant (MDR-TB) strains, has now been reported in 100 countries around the world.
Device can be used in the field without special equipment, according to developers
The technique involved transplanting what are known as olfactory ensheathing cells into the patient's spinal cord and constructing a "nerve bridge" between two stumps of the damaged spinal column.
The meeting in Cuba is aimed at keeping Ebola at bay and it brings together senior officials from the ALBA bloc of nations
Wildlife conservationists have struggled to reverse a decline in numbers of several African species, undermined by ferocious poaching by gangs which mostly ship the ivory to Asia.
Jerald Dennis is feeling stigmatized by his neighbors and has been shunned by his friends
Peru's 2,679 glaciers, spread over 19 snow-capped mountain ranges, are the source of the vast majority of the country's drinking water.
Some 85 percent of people said they thought the disease spread through sneezing or coughing, despite the fact that the World Health Organization regards that type of transmission as unlikely
No approved specific drug or treatment available for battling fatal pandemic virus hitting many West African countries
The death toll so far in the outbreak, first reported in Guinea in March, has reached 4,447 from a total of 8,914 cases, said WHO Assistant Director General Bruce Aylward.
The world's fifth-largest user of nuclear power has around 70 percent, or nearly 9,000 tonnes, of its used fuel stacked in temporary storage pools
The Supreme Council of Health said the infected was a 71-year-old Qatari national who suffered diabetes mellitus, according to the official Qatari news agency
Several airlines have cut flights to the region and there are reports of countries not allowing air ambulances to make refueling stops
A top U.N. official said response to a $1 billion funding appeal had been slow and that a surge in trained healthcare personnel was needed to tackle the crisis
The findings show the pressing need to detect lung cancer before it has shape-shifted into multiple malignant clones.